Otlertuzumab: Difference between revisions
CSV import |
No edit summary |
||
| Line 65: | Line 65: | ||
{{medicine-stub}} | {{medicine-stub}} | ||
{{No image}} | {{No image}} | ||
Latest revision as of 13:04, 18 March 2025
| Otlertuzumab | |
|---|---|
| [[File:|frameless|220px|alt=|]] | |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Otlertuzumab is a monoclonal antibody designed for the treatment of certain types of cancer. It specifically targets the CD37 protein, a molecule predominantly expressed on the surface of B cells, which are a type of white blood cell involved in the immune response. Otlertuzumab binds to CD37 on B cells, leading to the destruction of these cells, which is beneficial in conditions where B cells become cancerous, such as in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL).
Mechanism of Action[edit]
Otlertuzumab works by binding to the CD37 antigen on B cells. This binding initiates a series of events that lead to cell death, primarily through mechanisms such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). The drug's action is selective, mainly affecting B cells, which makes it a targeted therapy offering potential benefits in terms of reduced side effects compared to more traditional chemotherapy agents.
Clinical Trials[edit]
Otlertuzumab has been evaluated in several clinical trials, particularly focusing on its efficacy and safety in patients with CLL and NHL. These studies have explored its use both as a monotherapy and in combination with other chemotherapeutic agents, assessing outcomes such as response rate, progression-free survival, and overall survival.
Pharmacokinetics[edit]
The pharmacokinetic properties of otlertuzumab, including its absorption, distribution, metabolism, and excretion, are crucial for determining its dosage and administration schedule. These parameters help in optimizing the therapeutic efficacy while minimizing potential side effects.
Adverse Effects[edit]
Like all therapeutic agents, otlertuzumab can cause side effects. The most common adverse effects observed in clinical trials include infusion-related reactions, fatigue, nausea, and cytopenias. Severe reactions, although rare, may necessitate discontinuation of therapy or dose adjustments.
Future Directions[edit]
Research is ongoing to further define the role of otlertuzumab in cancer therapy, including its potential use in other B-cell malignancies and in combination with newer targeted therapies. Ongoing and future clinical trials will help to better understand its place in cancer treatment regimens.
See Also[edit]
